UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 10, 2025 NeuroOne Medical Technologies Corporation (Exact name of registrant as specified in its charter) Delaware 001-40439 27-0863354 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.) 7599 Anagram Dr., Eden Prairie, MN 55344 (Add ...

Total revenue of $6.3M Includes $3.3 Million of Product Revenue in Addition to a One-Time Upfront Payment of $3.0 Million in License Revenue from Zimmer Biomet EDEN PRAIRIE, Minn., Feb. 12, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (“NeuroOne” or the “Company”), a medical technology company dedicated to transforming the surgical diagnosis and treatment of neurological disorders, has reported financial results for the first quarter fiscal year 2025 ended December 31, 2 ...

EDEN PRAIRIE, Minn., Feb. 05, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, will release financial results for its fiscal first quarter ended December 31, 2024, before market open on February 12, 2025. Management will host an investor conference call and webcast at 8:30 a.m. eastern time on Wednesday, Febru ...

EDEN PRAIRIE, Minn., Feb. 04, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announced that it has regained compliance with the Nasdaq Capital Market’s continued listing standard for the minimum share price requirements under Nasdaq Listing Rule 5550(a)(2). The Company received a letter on February 3, ...

Core Viewpoint - NeuroOne Medical Technologies Corporation reported a significant increase in revenue for the first quarter of fiscal 2025, driven by collaboration revenue and product sales, indicating strong growth potential in the medical technology sector focused on neurological disorders [1][2][3]. Revenue Highlights - Total revenue for the first quarter of fiscal 2025 is expected to reach a record $6.2 million, a substantial increase from $1.0 million in the same quarter of fiscal 2024 [2]. - The revenue includes a one-time upfront payment of $3.0 million from a collaboration with Zimmer Biomet, which is part of an expanded distribution agreement for the OneRF™ Ablation System [2][4]. - Product revenues are projected to increase by 227% to $3.2 million in the first quarter of fiscal 2025, compared to $1.0 million in the first quarter of fiscal 2024 [3]. Future Guidance - For the full fiscal year 2025, the company maintains its guidance for product revenues, excluding collaboration revenues, to be between $8.0 million and $10.0 million, with product gross margins expected to range from 47% to 51% [3]. Business Operations - The increase in expected revenue is attributed to higher-than-anticipated product sales as the partner, Zimmer Biomet, builds inventory and implements NeuroOne's products and technology with customers [4]. - A virtual investor webinar is scheduled to discuss business operations and recent updates, including the collaboration with Zimmer Biomet [5][6]. Company Overview - NeuroOne Medical Technologies Corporation focuses on developing minimally invasive and high-definition solutions for neurological disorders, aiming to improve patient outcomes and reduce procedural costs [8].

Core Viewpoint - NeuroOne Medical Technologies Corporation is set to provide an overview of its business model and anticipated revenue growth for fiscal year 2025, following a significant increase in product revenue in fiscal year 2024 [1][2]. Group 1: Business Model and Revenue Growth - The company has recently expanded its exclusive distribution agreement with Zimmer Biomet, a leading medical device manufacturer [2]. - Product revenue for fiscal year 2024 grew by 77% to $3.5 million, and the company expects revenue to rise to between $8 million and $10 million in fiscal year 2025, indicating a growth of 132% to 190% [2]. Group 2: Upcoming Investor Webinar - A virtual investor webinar is scheduled for January 10, 2025, where the CEO will present the business model and recent achievements, followed by a Q&A session [3]. - Participants are encouraged to join at least five minutes early to ensure timely participation [3]. Group 3: Company Overview - NeuroOne is focused on developing minimally invasive and high-definition solutions for EEG recording, brain stimulation, and ablation for various neurological disorders, aiming to improve patient outcomes and reduce procedural costs [5]. - The company may also explore applications in other areas such as depression, mood disorders, and artificial intelligence [5].

Business Model and Revenue Projections - The company will hold a virtual roadshow webinar to discuss its business operations and recent updates, including an overview of its business model and recent milestone achievements [1][2] - The company recently expanded its exclusive distribution agreement with Zimmer Biomet, one of the world's largest medical device manufacturers [2] - Product revenue grew by 77% to $3.5 million in fiscal year 2024, and is expected to increase to between $8 and $10 million in fiscal year 2025, representing a growth of 132% to 190% [2] Webinar Details - The webinar will include a presentation followed by a Q&A session, accessible via webcast or dial-in numbers [3] - The webinar is scheduled for Thursday, January 9, 2025, at 11:00 a.m. Eastern Standard Time [3] - A playback of the call will be available through January 23, 2025 [4] Company Overview - NeuroOne Medical Technologies Corporation is focused on developing minimally invasive and hi-definition solutions for EEG recording, brain stimulation, and ablation for patients with neurological disorders such as epilepsy, Parkinson's disease, and chronic pain [5] - The company is also exploring applications in other areas including depression, mood disorders, pain, incontinence, high blood pressure, and artificial intelligence [5] Forward-Looking Statements - The press release contains forward-looking statements regarding the company's future performance, including expectations for significant product revenue growth and margin expansion in fiscal year 2025 [6] - These statements are based on current expectations and are subject to risks and uncertainties that could cause actual results to differ materially [6][7]

NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) Q4 2024 Earnings Conference Call December 17, 2024 9:00 AM ET Company Participants Dave Rosa - Chief Executive Officer Ron McClurg - Chief Financial Officer Conference Call Participants Operator Good day, ladies and gentlemen. Welcome to the NeuroOne Fourth Quarter and Fiscal Year-End 2024 Earnings Call. Today's call will be conducted by the company's Chief Executive Officer, Dave Rosa; and Ron McClurg, the company's Chief Financial Officer; Chris Volk ...

Exhibit 99.1 NeuroOne® Product Revenue Increases 77% to $3.5 Million in Fiscal 2024: Expects Product Revenue to Increase at Least 132% to at Least $8 Million in Fiscal 2025 Company's Exclusive Distribution Agreement with Zimmer Biomet included $3.0 Million Upfront Payment: Expected to Drive Revenue and Expand Margins Significantly EDEN PRAIRIE, Minn., December 17, 2024 -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) ("NeuroOne" or the "Company"), a medical technology company dedicated to transfo ...

Core Insights - NeuroOne Medical Technologies Corporation has expanded its exclusive distribution agreement with Zimmer Biomet, receiving a $3 million upfront payment, which is expected to significantly drive revenue and expand margins [1][2][3] Financial Highlights - Product revenue for fiscal year 2024 increased by 77% to $3.5 million from $2.0 million in fiscal year 2023 [2][9] - Operating expenses decreased by 12% to $3.0 million in Q4 2024 compared to $3.4 million in Q4 2023 [2][10] - The company expects product revenue for fiscal year 2025 to range between $8 million and $10 million, representing an increase of 132% to 190% compared to fiscal year 2024 [2][13] Operational Updates - The OneRF™ Ablation System has been placed in five prominent epilepsy centers, with positive outcomes reported from procedures performed on 12 patients [5] - The company is progressing discussions with strategic partners for additional use cases and has plans to submit a 510(k) application for a new trigeminal nerve ablation product in the first half of 2025 [4][6] Management Commentary - The CEO highlighted the partnership with Zimmer Biomet as a key driver for future revenue growth and margin expansion, with expectations of at least $8 million in revenue for fiscal year 2025 [3] Cash Position - As of September 30, 2024, the company had cash and cash equivalents of $1.5 million, down from $5.3 million a year earlier, but remains debt-free [12]